Your browser doesn't support javascript.
loading
Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
Smith, Joshua D; Ludwig, Megan L; Bhangale, Apurva D; Brummel, Collin; Swiecicki, Paul L; Worden, Francis P; Chinn, Steven B; Stucken, Chaz L; Rosko, Andrew J; Prince, Mark E P; Malloy, Kelly M; Casper, Keith A; Bradford, Carol R; Chepeha, Douglas B; Shah, Jennifer; Schonewolf, Caitlin A; McHugh, Jonathon B; Nyati, Mukesh K; Eisbruch, Avraham; Mierzwa, Michelle L; Spector, Matthew E; Brenner, J Chad.
Affiliation
  • Smith JD; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Ludwig ML; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Bhangale AD; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Brummel C; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Swiecicki PL; Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Worden FP; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Chinn SB; Division of Hematology & Oncology, Department of Internal Medicine, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Stucken CL; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Rosko AJ; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Prince MEP; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Malloy KM; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Casper KA; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Bradford CR; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Chepeha DB; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Shah J; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Schonewolf CA; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • McHugh JB; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Nyati MK; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Eisbruch A; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Mierzwa ML; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Spector ME; Rogel Cancer Center, University of Michigan Medical School, Ann Arbor, Michigan, USA.
  • Brenner JC; Department of Otolaryngology - Head & Neck Surgery, University of Michigan Medical School, Ann Arbor, Michigan, USA.
Head Neck ; 45(5): 1281-1287, 2023 05.
Article de En | MEDLINE | ID: mdl-36932871
BACKGROUND: We sought to characterize early changes in CD8+ tumor-infiltrating lymphocytes and tumor transcriptomes after induction cetuximab in a cohort with p16-positive oropharyngeal cancer on a phase II clinical de-escalation trial. METHODS: Tumor biopsies were obtained before and 1 week after a single cetuximab loading dose in eight patients enrolled in a phase II trial of cetuximab and radiotherapy. Changes in CD8+ tumor-infiltrating lymphocytes and transcriptomes were assessed. RESULTS: One week after cetuximab, five patients (62.5%) had an increase in CD8+ cell infiltration with a median (range) fold change of +5.8 (2.5-15.8). Three (37.5%) had unchanged CD8+ cells (median [range] fold change of -0.85 [0.8-1.1]). In two patients with evaluable RNA, cetuximab induced rapid tumor transcriptome changes in cellular type 1 interferon signaling and keratinization pathways. CONCLUSIONS: Within 1 week, cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content.
Sujet(s)
Mots clés
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'oropharynx Limites: Humans Langue: En Journal: Head Neck Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique
Texte intégral
Ajouter à My VHL
Imprimer
XML
PubMed Links
Recherche sur Google

Texte intégral: 1 Collection: 01-internacional Base de données: MEDLINE Sujet principal: Tumeurs de l'oropharynx Limites: Humans Langue: En Journal: Head Neck Sujet du journal: NEOPLASIAS Année: 2023 Type de document: Article Pays d'affiliation: États-Unis d'Amérique Pays de publication: États-Unis d'Amérique